Table of contents
This is a summary of the European public assessment report (EPAR). Its purpose is to explain how the assessment done by the Committee for Medicinal Products for Veterinary Use (CVMP) on the basis of the documentation provided, led to the recommendations on the conditions of use.
This summary cannot replace a face-to-face discussion with your veterinarian. If you need more information about your animal’s medical condition or treatment, contact your veterinarian. If you want more information on the basis of the CVMP recommendations, read the scientific discussion (also part of the EPAR).
Meloxoral : EPAR - Summary for the public (PDF/69.42 KB)
First published: 29/11/2010
Last updated: 29/11/2010
|Agency product number||
|International non-proprietary name (INN) or common name||
|Anatomical therapeutic chemical veterinary (ATCvet) codes||
This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see Generic and hybrid medicines.
Dechra Regulatory B.V.
|Date of issue of marketing authorisation valid throughout the European Union||
01/10/2021 Meloxoral - EMEA/V/C/000151 - IG/1444
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Anti-inflammatory and anti-rheumatic products, non-steroids
Alleviation of inflammation and pain in chronic musculoskeletal disorders.
Alleviation of inflammation and pain in both acute and chronic musculoskeletal disorders.
Meeting highlights from the Committee for Medicinal Products for Veterinary Use (CVMP) 19-20 January 202122/01/2021